NSCLC疾病负担评估：基于生存模型的荟萃分析研究
Assessment of NSCLC disease burden: A survival model-based meta-analysis study
影响因子:4.10000
分区:生物学3区 / 生化与分子生物学3区
发表日期:2024 Dec
作者:
Nataliya Kudryashova, Boris Shulgin, Nikolai Katuninks, Victoria Kulesh, Gabriel Helmlinger, Kirill Zhudenkov, Kirill Peskov
摘要
我们提出了一种通过综合生存模型来量化NSCLC疾病负担的荟萃分析方法。来自公共资源的汇总生存数据用于对早期的模型和高级NSCLC阶段进行参数化，并结合了化学疗法，靶向疗法和免疫疗法。基于各种分层和初始条件，在异质患者队列中预测总生存期（OS）。评估了药物经济学指标（获得的生命年（LYG）和质量调整后的寿命（QALY）），以量化专用治疗的益处并改善NSCLC的早期检测。模拟表明，引入晚期NSCLC亚组的新疗法增加了8.1个月（95％CI：5.9，10.0），在QALY中，LYG和1.65个月的相应增长率为2.9个月（95％CI：2.2，3.6）（95％CI：1.2，2.0）。 Scenarios representing improved detection of early cancer in the whole patient cohort, revealed up to 17.6 (95 % CI: 16.5, 19.0) and 15.7 months (95 % CI: 14.8, 16.6) increase in median survival, with respective gains of 6.2 months (95 % CI: 5.9, 6.4) and 5.2 months (95 % CI: 4.9, 5.4) in LYG and 6.6 months （95％CI：6.4，6.7）和6.0个月（95％CI：5.9，6.2）用于常规和最佳治疗。这个旨在表征癌症负担的综合建模平台，可以精确地量化专门疗法在治疗方案中引入专用疗法的累积益处，并在早期发现该疾病后生存延长。
Abstract
We present a meta-analytics approach to quantify NSCLC disease burden by integrative survival models. Aggregated survival data from public sources were used to parameterize the models for early as well as advanced NSCLC stages incorporating chemotherapies, targeted therapies, and immunotherapies. Overall survival (OS) was predicted in a heterogeneous patient cohort based on various stratifications and initial conditions. Pharmacoeconomic metrics (life years gained (LYG) and quality-adjusted life years (QALY) gained), were evaluated to quantify the benefits of specialized treatments and improved early detection of NSCLC. Simulations showed that the introduction of novel therapies for the advanced NSCLC sub-group increased median survival by 8.1 months (95 % CI: 5.9, 10.0), with corresponding gains of 2.9 months (95 % CI: 2.2, 3.6) in LYG and 1.65 months (95 % CI: 1.2, 2.0) in QALY. Scenarios representing improved detection of early cancer in the whole patient cohort, revealed up to 17.6 (95 % CI: 16.5, 19.0) and 15.7 months (95 % CI: 14.8, 16.6) increase in median survival, with respective gains of 6.2 months (95 % CI: 5.9, 6.4) and 5.2 months (95 % CI: 4.9, 5.4) in LYG and 6.6 months (95 % CI: 6.4, 6.7) and 6.0 months (95 % CI: 5.9, 6.2) in QALY for conventional and optimal treatment. This integrative modeling platform, aimed at characterizing cancer burden, allows to precisely quantify the cumulative benefits of introducing specialized therapies into the treatment schemes and survival prolongation upon early detection of the disease.